uniQure Receives 2017 Frost & Sullivan Manufacturing Leadership Award
(Thomson Reuters ONE) -
-- Lexington, MA-based Gene Therapy Facility Recognized for Enabling
Manufacturing Excellence --
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 03, 2017 (GLOBE NEWSWIRE)
-- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced
that it has been recognized by Frost & Sullivan as a 2017 Manufacturing
Leadership Awards winner for outstanding achievement in Engineering & Production
Technology Leadership related to its Lexington, Massachusetts gene therapy
manufacturing facility.
uniQure's Lexington-based facility is one of the largest, most versatile gene
therapy manufacturing facilities in the world. Over the past four years,
uniQure has invested more than $25 million in designing, constructing and
equipping its 55,000 square foot facility with state-of-the-art laboratories and
commercial-scale production capabilities. The facility offers 500-liter capacity
with the ability to expand to up to 2,000 liters when needed.
"The innovative design of our facility, which incorporated 3D modeling and
single-use components, required substantially less upfront capital expenditures
and enables us to operate at significantly lower costs compared to other
production systems," stated Lance Weed, vice president of operations for
uniQure. "Our use of disposable components in our manufacturing process reduces
the need for maintenance and testing, lowers the risk of contamination, enables
rapid product changeovers, and requires substantially less personnel to
operate."
"uniQure is committed to manufacturing excellence in gene therapy and we are
delighted that Frost & Sullivan has recognized our achievements in this regard,"
stated Matt Kapusta, chief executive officer of uniQure. "We continue to
believe that our leading manufacturing capabilities provide us a significant
competitive advantage in rapidly delivering gene therapies to patients,
including our lead product candidate in hemophilia B, for which we plan to begin
a global pivotal study in 2018."
uniQure will be recognized at the 13th Annual Manufacturing Leadership Awards
Gala, which is to be held on the last day of the Manufacturing Leadership
Summit, June 12-14, 2017 at the Hyatt Regency Huntington Beach Resort and Spa in
Huntington Beach, CA.
Additional Resources
* 2017 Manufacturing Leadership Award Winners
* About the 13(th) Annual Manufacturing Leadership Summit
* About the Manufacturing and Leadership Council
* About Frost and Sullivan
About uniQure
uniQure is delivering on the promise of gene therapy - single treatments with
potentially curative results. We are leveraging our modular and validated
technology platform to rapidly advance a pipeline of proprietary and partnered
gene therapies to treat patients with hemophilia, Huntington's disease and
cardiovascular diseases. www.uniQure.com
About the Frost & Sullivan Manufacturing Leadership Awards
The Frost & Sullivan Manufacturing Leadership Awards, now in their 13th year,
honor manufacturing companies and individual manufacturing leaders that are
shaping the future of global manufacturing. Winning projects and individual
manufacturing leaders have demonstrated achievement in one of a wide range of
categories, and are chosen by a panel of expert judges for results that have
delivered clear and compelling value, return on investment, and other tangible
outcomes. There will be several winners in each category, including one High
Achiever's Award in each category, as well as a 2017 Manufacturer of the Year
for both small and large enterprises. Also unveiled at the Gala will be the ML
Awards Manufacturing Leader of the Year and Lifetime Achievement Award winners.
The theme for the 13th Annual Manufacturing Leadership Summit is "Manufacturing
4.0 in Action." The event enables senior-level executives in all aspects of
manufacturing an opportunity to network with and learn from the best minds in
the industry
For more information on the Manufacturing Leadership Awards or the Manufacturing
Leadership Summit, please go to www.mlsummit.com.
uniQure Forward-Looking Statements
This press release contains forward-looking statements. All statements other
than statements of historical fact are forward-looking statements, which are
often indicated by terms such as "anticipate," "believe," "could," "estimate,"
"expect," "goal," "intend," "look forward to", "may," "plan," "potential,"
"predict," "project," "should," "will," "would" and similar expressions.
Forward-looking statements are based on management's beliefs and assumptions and
on information available to management only as of the date of this press
release. These forward-looking statements include, but are not limited to,
statements regarding the implementation and effects of the Company's new
strategic and organizational changes, the development of our gene therapy
product candidates, the success of our collaborations and the risk of cessation,
delay or lack of success of any of our ongoing or planned clinical studies
and/or development of our product candidates. Our actual results could differ
materially from those anticipated in these forward-looking statements for many
reasons, including, without limitation, risks associated with corporate
reorganizations and strategic shifts, collaboration arrangements, our and our
collaborators' clinical development activities, regulatory oversight, product
commercialization and intellectual property claims, as well as the risks,
uncertainties and other factors described under the heading "Risk Factors" in
uniQure's 2015 Annual Report on Form 20-F filed with the Securities and Exchange
Commission on April 4, 2016. Given these risks, uncertainties and other factors,
you should not place undue reliance on these forward-looking statements, and we
assume no obligation to update these forward-looking statements, even if new
information becomes available in the future.
uniQure Contacts:
Maria E. Cantor
Direct: 339-970-7536
Mobile: 617-680-9452
m.cantor(at)uniQure.com
Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79
e.mulder(at)uniQure.com
Tom Malone
Direct: 339-970-7558
Mobile: 339-223-8541
t.malone(at)uniQure.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: uniQure N.V. via GlobeNewswire
Datum: 03.03.2017 - 13:00 Uhr
Sprache: Deutsch
News-ID 528006
Anzahl Zeichen: 7347
contact information:
Town:
Amsterdam
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 287 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"uniQure Receives 2017 Frost & Sullivan Manufacturing Leadership Award"
steht unter der journalistisch-redaktionellen Verantwortung von
uniQure N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
